Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2015 · 10-Q
Revenue$21.61K$21.61K— vs Q3 2014 Net Income-$1.70M-$1.70MN/M vs Q3 2014 EPS Diluted-$0.04-$0.04— vs Q3 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
-$1,691,283
N/M
Operating Cash Flowderived$8,509— Margins · derivedGross margin-51.9%
Operating margin-7826.4%
Net margin-7883.8%
ended Sep 30, 2015 · filed Nov 23, 2015 · 54 d after period end